Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin

48Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Ranpirnase (Rap) is a cytotoxic ribonuclease (RNase) isolated from frog oocytes. Here we describe high antitumor activity of a novel immunotoxin, 2L-Rap-hLL1-γ4P, composed of 2 Rap molecules, each fused to the N terminus of the light chain of hLL1, an internalizing anti-CD74 humanized antibody. To reduce unwanted side effects, the constant region of hLL1 was changed from γ1 to γ4 and further to γ4P by replacing serine228 to proline to prevent the formation of a half immunoglobulin G (IgG) common for IgG4. In vitro, 2L-Rap-hLL1-γ4P retained RNase activity, specific binding to CD74, and was significantly more potent against CD74+ cell lines (Daudi, Raji, and MC/CAR) than naked hLL1. In vivo, the pharmacokinetic profile of 2L-Rap-hLL1-γ4P was similar to that of naked hLL1. The maximum tolerated dose of 2L-Rap-hLL1-γ4P in severe combined immunodeficient mice (SCID) or BALB/c mice was 50 μg per mouse. In Raji and Daudi Burkitt lymphoma xenograft models, treatment with a single 5 to 50 μg dose of 2L-Rap-hLL1-γ4P, given as early or delayed treatment, resulted in cures of most animals. Treatment with 2L-Rap-hLL1-γ4P was significantly better than all controls, including saline, naked hLL1, and nonspecific immunotoxin. In conclusion, 2L-RaphLL1-γ4P demonstrated excellent in vitro and in vivo efficacy and thus merits further consideration as a therapeutic for CD74+ tumors. © 2005 by The American Society of Hematology.

References Powered by Scopus

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

489Citations
N/AReaders
Get full text

Role for intracellular proteases in the processing and transport of class II HLA antigens

374Citations
N/AReaders
Get full text

Ribonuclease A variants with potent cytotoxic activity

220Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Targeted therapy of cancer: New prospects for antibodies and immunoconjugates

229Citations
N/AReaders
Get full text

CD74: A new candidate target for the immunotherapy of B-cell neoplasms

194Citations
N/AReaders
Get full text

CD74: An emerging opportunity as a therapeutic target in cancer and autoimmune disease

132Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Chang, C. H., Sapra, P., Vanama, S. S., Hansen, H. J., Horak, I. D., & Goldenberg, D. M. (2005). Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin. Blood, 106(13), 4308–4314. https://doi.org/10.1182/blood-2005-03-1033

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 10

48%

Researcher 7

33%

Professor / Associate Prof. 3

14%

Lecturer / Post doc 1

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 12

46%

Agricultural and Biological Sciences 11

42%

Biochemistry, Genetics and Molecular Bi... 2

8%

Computer Science 1

4%

Save time finding and organizing research with Mendeley

Sign up for free